Novel 1,6-naphthyridin-2(1H)-ones as potential anticancer agents targeting Hsp90.

Abstract : Hsp90 is an ATP-dependent chaperone known to be overexpressed in many cancers. This way, Hsp90 is an important target for drug discovery. Novobiocin, an aminocoumarin antibiotic, was reported to inhibit Hsp90 targeting C-terminal domain, and showed anti-proliferative properties, leading to the development of new and more active compounds. Consequently, a new set of novobiocin analogs derived from 1,6-naphthyridin-2(1H)-one scaffold was designed, synthesized and evaluated against two breast cancer cell lines. Subsequently, cell cycle progression and apoptosis were conducted on best candidates, finally Western Blot analysis was performed to measure their ability to induce degradation of Hsp90 client proteins.
Type de document :
Article dans une revue
European Journal of Medicinal Chemistry, Elsevier, 2016, 119, pp.17-33. 〈10.1016/j.ejmech.2016.04.050〉
Liste complète des métadonnées

Littérature citée [31 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-01334013
Contributeur : Elizabeth Bernardo <>
Soumis le : lundi 20 juin 2016 - 12:05:52
Dernière modification le : jeudi 5 avril 2018 - 10:36:50

Fichier

 Accès restreint
Fichier visible le : jamais

Connectez-vous pour demander l'accès au fichier

Identifiants

Collections

Citation

David Montoir, Sophie Barillé-Nion, Alain Tonnerre, Philippe Juin, Muriel Duflos, et al.. Novel 1,6-naphthyridin-2(1H)-ones as potential anticancer agents targeting Hsp90.. European Journal of Medicinal Chemistry, Elsevier, 2016, 119, pp.17-33. 〈10.1016/j.ejmech.2016.04.050〉. 〈inserm-01334013〉

Partager

Métriques

Consultations de la notice

78